Clinical Study Results

Publication of Clinical Study Results

Since 2020, Gilead discloses clinical study results of newly authorized treatments in Switzerland by Swissmedic according to the requirements laid out in Art. 71-73 TPO (Ordinance on Therapeutic Products).

Therapies are listed in alphabetical order.

Product Active Substance Authorization Number Date of Authorization
Sunlenca® Lenacapavir 68385 / 68386 07.07.2023
Tecartus® Autologous anti-CD19-transducedCD3+ cells 67884 25.08.2021
Trodelvy® Sacituzumab govitecan 68179 09.09.2021
Veklury® Remdesivir 68026 / 68043 25.11.2020